Literature DB >> 25707860

Bioactivity in an Aggrecan 32-mer Fragment Is Mediated via Toll-like Receptor 2.

Sophie Lees1, Suzanne B Golub, Karena Last, Weiguang Zeng, David C Jackson, Philip Sutton, Amanda J Fosang.   

Abstract

OBJECTIVE: To determine whether an aggrecan 32-mer fragment derived from dual ADAMTS and matrix metalloproteinase (MMP) cleavage in the aggrecan interglobular domain was bioactive and, if so, to elucidate its mechanism of action.
METHODS: Mouse primary chondrocytes, synovial fibroblasts, or peritoneal macrophages, human primary chondrocytes, and cells or cell lines from myeloid differentiation factor 88 (MyD88)-deficient and Toll-like receptor 2 (TLR-2)-deficient mice were stimulated with synthetic mouse 32-mer peptide, human 32-mer peptide, a 32-mer scrambled peptide, or native, glycosylated 32-mer peptide. Cells stimulated with 32-mer peptide were analyzed for changes in messenger RNA (mRNA) expression by quantitative polymerase chain reaction. Conditioned medium was analyzed for levels of interleukin-6 protein by an AlphaLISA or for levels of MMP-3 and MMP-13 protein by Western blotting. NF-κB activation was measured in a luciferase reporter assay.
RESULTS: Treatment of mouse cells or cartilage explants with 32-mer peptide or scrambled peptide revealed that the 32-mer peptide, but not the scrambled peptide, had antianabolic, procatabolic, and proinflammatory bioactivity in vitro. Chondrocytes, synovial fibroblasts, and macrophages from MyD88-deficient mice failed to respond to 32-mer peptide stimulation. A macrophage cell line derived from TLR-2-deficient mice also failed to respond to 32-mer peptide stimulation. Stimulation of human chondrocytes with human 32-mer peptide increased the expression of catabolic markers at the mRNA and protein levels. Mouse and human 32-mer peptide stimulated NF-κB activation in a TLR-2-dependent reporter assay, and the response of chondrocytes from both species to native, glycosylated 32-mer peptide was similar to the response to synthetic peptides.
CONCLUSION: The aggrecan 32-mer fragment is a novel endogenous ligand of TLR-2 with the potential to accelerate cartilage destruction in vivo.
© 2015, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25707860     DOI: 10.1002/art.39063

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  38 in total

Review 1.  Osteoarthritis year in review 2015: biology.

Authors:  A M Malfait
Journal:  Osteoarthritis Cartilage       Date:  2016-01       Impact factor: 6.576

Review 2.  An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis.

Authors:  Rachel E Miller; Carla R Scanzello; Anne-Marie Malfait
Journal:  Semin Immunopathol       Date:  2019-10-14       Impact factor: 9.623

3.  Adamts5-/- Mice Exhibit Altered Aggrecan Proteolytic Profiles That Correlate With Ascending Aortic Anomalies.

Authors:  Loren E Dupuis; E Lockett Nelson; Brittany Hozik; Sarah C Porto; Alexandra Rogers-DeCotes; Amanda Fosang; Christine B Kern
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-08-01       Impact factor: 8.311

Review 4.  The danger from within: alarmins in arthritis.

Authors:  Meriam Nefla; Dirk Holzinger; Francis Berenbaum; Claire Jacques
Journal:  Nat Rev Rheumatol       Date:  2016-10-13       Impact factor: 20.543

Review 5.  Danger-Associated Molecular Patterns Derived From the Extracellular Matrix Provide Temporal Control of Innate Immunity.

Authors:  Charles W Frevert; Jessica Felgenhauer; Malgorzata Wygrecka; Madalina V Nastase; Liliana Schaefer
Journal:  J Histochem Cytochem       Date:  2018-01-01       Impact factor: 2.479

Review 6.  Inflammation in osteoarthritis: is it time to dampen the alarm(in) in this debilitating disease?

Authors:  M H J van den Bosch
Journal:  Clin Exp Immunol       Date:  2018-11-28       Impact factor: 4.330

7.  An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2.

Authors:  Rachel E Miller; Shingo Ishihara; Phuong B Tran; Suzanne B Golub; Karena Last; Richard J Miller; Amanda J Fosang; Anne-Marie Malfait
Journal:  JCI Insight       Date:  2018-03-22

Review 8.  Role of low-grade inflammation in osteoarthritis.

Authors:  Carla R Scanzello
Journal:  Curr Opin Rheumatol       Date:  2017-01       Impact factor: 5.006

Review 9.  Does lipopolysaccharide-mediated inflammation have a role in OA?

Authors:  Zeyu Huang; Virginia Byers Kraus
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

Review 10.  Aggrecan in Cardiovascular Development and Disease.

Authors:  Christopher D Koch; Chan Mi Lee; Suneel S Apte
Journal:  J Histochem Cytochem       Date:  2020-09-01       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.